TY - JOUR
T1 - Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections
AU - Douglas, Ed
AU - Wulandari, Sri Wijayanti
AU - Lovell, Scott
AU - Laabei, Maisem
N1 - Funding Information:
This work was supported by the Academy of Medical Sciences Springboard Award (SBF006\1023: M. Laabei) and the Beasiswa Pendidikan Indonesia Scholarship (S.W. Wulandari).
Publisher Copyright:
© 2023 The Authors. Microbial Biotechnology published by Applied Microbiology International and John Wiley & Sons Ltd.
PY - 2023/5/13
Y1 - 2023/5/13
N2 - Antimicrobial resistance is a major obstacle for the treatment of infectious diseases and currently represents one of the most significant threats to global health. Staphylococcus aureus remains a formidable human pathogen with high mortality rates associated with severe systemic infections. S. aureus has become notorious as a multidrug resistant bacterium, which when combined with its extensive arsenal of virulence factors that exacerbate disease, culminates in an incredibly challenging pathogen to treat clinically. Compounding this major health issue is the lack of antibiotic discovery and development, with only two new classes of antibiotics approved for clinical use in the last 20 years. Combined efforts from the scientific community have reacted to the threat of dwindling treatment options to combat S. aureus disease in several innovative and exciting developments. This review describes current and future antimicrobial strategies aimed at treating staphylococcal colonization and/or disease, examining therapies that show significant promise at the preclinical development stage to approaches that are currently being investigated in clinical trials.
AB - Antimicrobial resistance is a major obstacle for the treatment of infectious diseases and currently represents one of the most significant threats to global health. Staphylococcus aureus remains a formidable human pathogen with high mortality rates associated with severe systemic infections. S. aureus has become notorious as a multidrug resistant bacterium, which when combined with its extensive arsenal of virulence factors that exacerbate disease, culminates in an incredibly challenging pathogen to treat clinically. Compounding this major health issue is the lack of antibiotic discovery and development, with only two new classes of antibiotics approved for clinical use in the last 20 years. Combined efforts from the scientific community have reacted to the threat of dwindling treatment options to combat S. aureus disease in several innovative and exciting developments. This review describes current and future antimicrobial strategies aimed at treating staphylococcal colonization and/or disease, examining therapies that show significant promise at the preclinical development stage to approaches that are currently being investigated in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85159195424&partnerID=8YFLogxK
U2 - 10.1111/1751-7915.14268
DO - 10.1111/1751-7915.14268
M3 - Review article
SN - 1751-7915
JO - Microbial Biotechnology
JF - Microbial Biotechnology
ER -